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INTRODUCTION
The latest National Comprehensive Cancer Network (NCCN)
practical guideline recommends that most oropharyngeal cancers
be treated by concurrent chemoradiotherapy (CCRT), rather than
by surgery with or without adjuvant therapy. In fact, surgery is
viewed as the equivalent of definite radiotherapy (RT) for only
T1-2, N0-1 cancers. This guideline implies that the treatment
outcomes of RT and CCRT are better than or equivalent to that
of surgery with or without adjuvant RT, which is the traditional
treatment protocol. 
However, head and neck surgeons have been faced with two
major changes in the clinical environment. One is the health-
related quality of life (QOL) issue. Patients and surgeons now
acknowledge that QOL is one of the important parameters
when evaluating treatment outcome in head and neck cancer.
The oropharynx is a cardinal region for swallowing and speak-
ing, and accordingly, QOL should be a key consideration in the
treatment of oropharyngeal cancer. The second major change
involves the development of more conservative surgical tech-
niques and of functional reconstructions. Traditionally surgery for
oropharyngeal cancer often required highly invasive approaches,
such as, mandibular swing or mandibular lingual release, to
secure a wide operation field. However, several transoral
approaches have been introduced and many reports have demon-
strated that transoral techniques are associated with less morbidity
and are oncologically safe. As for reconstruction, along with three-
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dimensional fitting, evolved flaps such as the sensate flap, the
freestyle perforator flap have been devised that offer consider-
able functional and cosmetic improvement. Consequently,
oropharyngeal surgery is now associated with fewer morbidi-
ties. Although a small number of studies have compared
surgery-based and RT-based treatments, few have simultane-
ously compared the treatment outcomes and QOL. In addition,
since intraoral procedures are generally conducted when oper-
ating oropharyngeal cancers at our institution, we suspected
that patients treated with a surgery-based modality might have
achieved better QOLs than those treated with a RT-based
method. 
In this study, we compared the treatment outcomes and the
health-related QOLs of oropharyngeal cancer patients treated
by surgery-based versus RT-based modalities. In addition, we
evaluated the adequacy of surgery-based treatment as a first-line
therapy for oropharyngeal cancer. 
MATERIALS AND METHODS
Patients 
From 1995 to 2007, all 228 patients who were diagnosed with
oropharyngeal cancer in the Department of Otorhinolaryngology-
Head and Neck Surgery at Samsung Medical Center were
enrolled. Of these 228 patients, 95 were excluded due to dou-
ble or multiple primary cancers, referral after any curative-intent
treatment, a proven pathology other than squamous cell carci-
noma, or an incomplete medical record. The final number of
eligible patients was 133. 
These 133 patients were allocated to one of two groups: a
surgery-based treatment group or a RT-based treatment group.
Treatment modalities for all patients had been discussed previ-
ously by the tumor board. The surgery-based group included
the patients who underwent surgery only, surgery with adjuvant
RT, or surgery with adjuvant CCRT. The RT-based group con-
sisted of those who underwent RT only or CCRT. At our insti-
tution, other treatment protocols, such as, induction chemother-
apy followed by surgery or CCRT were not used. The radiation
dose of the postoperative setting was usually not more than 6,000
cGy, while the radiation dose in the RT-based treatment proto-
col was usually about 7,000 cGy. The most commonly used
chemotherapeutic agents were cisplatin with or without doc-
etaxel in both treatment groups.
Medical records were retrospectively reviewed and several
variables, including age, gender, primary tumor site, and TNM
stage were compared between the two study groups. The Mann-
Whitney test was used for age and RT dose comparison, and
the chi-square test was used for other variables. 
Treatment outcomes 
Kaplan-Meier survival analysis was performed in each group.
First, the three-year overall survival rates (OSR), disease-free
survival rates (DFSR), locoregional control rates (LRCR) and
their respective standard errors were determined using survival
Tables. Next, Z values of the standard normal distribution were
calculated with the pertinent survival rates and standard errors.
Final P-values for testing the difference of treatment outcomes
between the two groups were determined based on Z values.
This whole analysis was repeated based on T classification (T1,
2 vs. T3, 4). Kaplan-Meier survival curves were also drawn. 
Quality of life 
QOL questionnaires were completed by telephone interview.
The interviewers were doctors in our department who had been
specifically trained for questionnaire. To eliminate bias, the inter-
viewers were not provided with patients’ information, aside
from their telephone numbers. This QOL survey and the whole
study design were approved by our institutional review board.
Thirty-seven patients had expired at the time of the survey,
13 could not be contacted, and two patients refused the survey,
and thus, 81 patients were analyzed for QOL. 
The questionnaires used in this study were the Korean ver-
sion of the European Organization for Research and Treatment
of Cancer Quality of Life Questionnaire (EORTC QLQ) validat-
ed by Yun et al. (1). The EORTC QLQ is composed of 30 core
questions (C30) and many other cancer-specific modules. The
head and neck cancer module containing 35 questions (HN35)
was used with C30 in this study after obtaining permission from
EORTC. The EORTC QLQ-C30 contains 15 items including
one global health status/QOL, five functional scales, and nine
symptom scales. In terms of global health status/QOL and func-
tional scales, the greater the score, the better the status or func-
tion is, whereas the converse applies to the symptom scales. The
EORTC QLQ-HN35 contains 18 symptom scale items. Therefore,
the greater the score, the more severe the symptoms are in the
head and neck region. All scores of QLQ-C30 and QLQ-HN35
were linear-transformed using the EORTC scoring manual to fit
the range 0-100. To eliminate the possible confounding effect
of T classification, which was the only variable that was signifi-
cantly different between the two groups, patients were catego-
rized into T1, 2 and T3, 4 and analyzed by Spearman’s partial
correlation test. All statistical analyses were carried out by the
professional statistical support team at our institution.
RESULTS
Demographics and characteristics of the two treatment
groups 
There were 104 men and 29 women (M:F ratio 3.6:1) with a
mean age of 61.5 years (range, 15 to 84 years) in the study sam-
ple. The follow-up period ranged from 1 to 155 months (average
of 43.7 months), and the number of patients allocated to theKim TW et al.: Treatment Outcomes and QOL in Oropharyngeal Cancer 155
surgery-based and RT-based groups were 66 and 67, respectively.
The characteristics of each treatment group are listed in
Tables 1 and 2. Age, gender, and primary tumor location were
not significantly different between the two groups. In the surgery-
based group, 40 operations were performed intraorally includ-
ing five laser resections. In 26 cases, operations were conducted
using a more invasive approach, such as, a pull-through, mandibu-
lar swing, and mandibular lingual release. 
T classification was significantly lower in the surgery-based
group, but overall TNM staging was not different between the
two groups because many patients were N2 or N3, consequent-
ly, fell into stage IV. 
The mean RT dose in the RT-based group was 6,637 cGy rang-
ing from 1,800 to 7,200, while the mean RT dose of surgery-based
group was mean 4,632 cGy, ranging from 0 to 7,000. After the
exclusion of patients who had undergone surgery only, the mean
RT dosage of surgery-based group was 5,878 cGy, and the dif-
ference of RT dose between the two groups was significantly
different (P<0.0001). 
Chemotherapeutic agents were also compaired. Cisplatin with
or without decetaxel comprise 80% of surgery-based group and
77.8% of RT-based group, and it was not different statistically
(P=0.443).
Characteristics Surgery-based RT-based P-value
Table 1. Characteristics of the surgery-based and RT-based treat-
ment groups
Mean age (SD)                   60.6 years (12.1)  62.4 years (9.9) 0.350
Gender (male:female)                 51:15                    53:14 0.836
Tumor location No. of patients (%) 0.365
Tonsillar area 41 (62.1) 47 (70.1)
Base of tongue 11 (16.7) 12 (17.9)
Soft palate 10 (15.2) 5 (7.5)
Lateral or posterior wall 2 (3.0) 3 (4.5)
Others 2 (3.0) 0 (0.0)
Treatment modality                        No. of patients (%)
Surgery only 14 (21.2)                     NR
Surgery+RT 47 (71.2)                     NR
Surgery+CCRT 5 (7.6)                      NR
RT only                                          NR 22 (33.3)
CCRT                                        NR 45 (66.7)
Total 66 (100) 67 (100)
*Patients who underwent surgery only were excluded. 
RT: radiotherapy; SD: standard deviation; CCRT: concurrent chemoradio-
therapy; NR: no relevant data.
Stage
No. of patients (%)
P-value
Surgery-based RT-based
Table 2. Stage characteristics of the surgery-based and RT-based
treatment groups
T classification 0.004
1 22 (33.3) 6 (9.0)
2 29 (43.9) 36 (53.7)
3 6 (9.1) 14 (20.9)
4 9 (13.6) 11 (16.4)
N classification 0.310
0 18 (27.3) 15 (22.4)
1 8 (12.1) 8 (11.9)
2 34 (51.5) 40 (59.7)
3 6 (9.1) 4 (6.0)
Stage 0.357
I 8 (12.1) 3 (4.5)
II 7 (10.6) 11 (16.4)
III 7 (10.6) 8 (11.9)
IV 44 (66.7) 45 (67.2)






Table 3. Treatment outcomes in the surgery-based and RT-based
treatment groups
3 years- T1, 2 0.863 (0.0481) 0.700 (0.0779) 0.149
OSR (SE) T3, 4 0.667 (0.1217) 0.686 (0.1010) 1.000
Total 0.814 (0.0485) 0.700 (0.0606) 0.141
3 years- T1, 2 0.815 (0.0595) 0.851 (0.0700) 1.000
DFSR (SE) T3, 4 0.700 (0.1449) 0.804 (0.0882) 1.000
Total 0.747 (0.0591) 0.757 (0.0576) 0.905
3 years- T1, 2 0.934 (0.0369) 0.877 (0.0672) 0.911
LRCR (SE) T3, 4 0.900 (0.0949) 0.850 (0.0798) 1.000
Total 0.824 (0.0485) 0.776 (0.0560) 0.518
RT: radiotherapy; OSR: overall survival rate; SE: standard error; DFSR:
disease-free survival rate; LRCR: locoregional control rate. 
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Treatment outcomes
Three-year OSRs, DFSRs, and LRCRs are shown in Table 3.
Survival rates were not significantly different between the two
treatment groups. All survival rates which were categorized
into T1, 2 and T3, 4 were also not statistically different. Kaplan-
Meier survival curves are shown in Figs. 1 to 3.
Quality of life 
The number of patients who completed the QOL survey in the
surgery-based and RT-based groups were 42 and 39, respec-
tively. The EORTC QLQ-C30 scores of two treatment groups
are shown in Table 4. The surgery-based group had a better
average QOL score for five items, namely, global health sta-
Fig. 2. Disease-free survival curves in the surgery-based and radiothera-
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Fig. 3. Locoregional control curves in the surgery-based and radiothera-
















T1, 2 T3, 4
P-value
Surgery (n=37) RT (n=27) Surgery (n=5) RT (n=12)
Table 4. EORTC QLQ-C30 scores in the surgery-based and RT-based treatment groups
Global health status/QOL 82.21 (20.14) 70.99 (21.36) 63.33 (9.50) 50.69 (25.98) 0.0267
Functional scales
Physical functioning 91.89 (11.67) 88.64 (21.55) 88.00 (16.60) 70.00 (25.82) 0.3949
Role functioning 90.99 (16.94) 89.51 (21.75) 86.67 (18.26) 54.17 (29.41) 0.4339
Emotional functioning 90.99 (15.39) 82.41 (23.83) 93.33 (9.13) 72.22 (28.94) 0.2231
Cognitive functioning 92.34 (13.94) 84.57 (23.08) 100.00 (0.00) 68.06 (21.86) 0.0157
Social functioning 95.95 (13.27) 84.57 (29.92) 90.00 (14.91) 62.50 (35.62) 0.0276
Symptom scales
Fatigue 11.41 (18.24) 15.64 (18.04) 17.78 (6.09) 40.74 (28.95) 0.2455
Nausea and vomiting 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 13.89 (13.91) 0.0379
Pain 6.31 (15.39) 6.79 (15.51) 10.00 (14.91) 22.22 (20.52) 0.4575
Dyspnea 5.41 (14.73) 4.94 (15.20) 20.00 (29.82) 11.11 (21.71) 0.6289
Insomnia 6.31 (15.39) 17.28 (28.30) 6.67 (14.91) 22.22 (25.95) 0.1068
Appetite loss 1.80 (7.64) 7.41 (16.88) 26.67 (36.52) 30.56 (30.01) 0.0939
Constipation 4.50 (11.55) 6.17 (16.11) 6.67 (14.91) 16.67 (22.47) 0.4601
Diarrhea 1.80 (7.64) 1.23 (6.41) 6.67 (14.91) 22.22 (25.95) 0.4933
Financial difficulties 4.50 (17.85) 16.05 (25.10) 6.67 (14.91) 38.89 (34.33) 0.0063
Values are presented as mean (standard deviation). 
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tus/QOL, cognitive functioning, social functioning, nausea and
vomiting, and financial difficulties, whereas the RT-based group
did not have a better score than the surgery-based group for
any QOL item. The average scores of the other 10 items were
not significantly different between the two groups.
Table 5 shows the results from the analysis for EORTC QLQ-
HN35. Likewise in QLQ-C30, no items showed an advantage
for the RT-based group. Three items, that is, dry mouth, pain
killers, and weight gain, were superior in the surgery-based group.
The majority of QLQ-HN35 items were not significantly differ-
ent between the two groups. 
DISCUSSION
Treatment outcomes 
According to the NCCN guideline, CCRT should be considered
the first-line treatment for the majority of oropharyngeal can-
cers, but evidence supporting this guideline is questionable. In a
review of recent reports, five-year survival rates in oropharyn-
geal cancer ranged from 45 to 70% for surgery followed by RT
(2-5), whereas for CCRT, the majority of studies conducted in
patients with advanced stage disease found three-year survival
rates in the range 37 to 51% (6-8). Although patients in the CCRT
studies appeared to have higher stage disease than in the surgery
followed by RT studies, treatment outcomes of CCRT are far
from satisfactory. 
Comparative reports on surgery-based and RT-based treat-
ment of oropharyngeal cancer are scarce. Soo et al. (9) reported
no significant three-years DFSR difference between surgery with
adjuvant RT and CCRT (50 vs. 40%, respectively) in 119 patients
with stage III/IV head and neck cancers. This study was the first
randomized controlled study to focus on the results of CCRT in
overall head and neck cancer, but it included only 25 patients
with oropharyngeal cancer (surgery+RT 12 and CCRT 13).
Moreover, organ preservation was possible in only 24% of
patients (6 out of 25), which shows that the oropharynx is a less
satisfactory site for organ preservation than the larynx, which
was preserved in 71.4% of patients (10 out of 14). Lanza et al.
(8) compared the results of surgery with RT and neoadjuvant
chemotherapy followed by RT in 115 T3-4 patients. The three-
years OSRs of the respective treatment groups were 82 and
49%, showing that surgery-based therapy appeared to be the
better treatment option. However, in their study, stage stratifi-
cation was not conducted and their RT was not based on a stan-
dard “concurrent” protocol.
In our study, the choice of treatment modalities may have
been subject to physicians’ bias. However, all factors consid-
ered to be able to influence prognosis were evaluated and no
factor except T classification turned out to be significantly dif-
ferent in the surgery-based and RT-based treatment groups.
Furthermore, the difference in T classification is considered to
have had little impact on our survival rates, because overall
stages were not different between the two groups. Actually
subgroup analysis based on T classification (T1, 2 vs. T3, 4) also
revealed no difference in all survival rates between the two
Item
T1, 2 T3, 4
P-value
Surgery (n=37) RT (n=27) Surgery (n=5) RT (n=12)
Table 5. EORTC QLQ-HN35 scores in the surgery-based and RT-based treatment groups
Pain  7.21 (16.45) 7.41 (14.31) 13.33 (9.50) 18.75 (19.82) 0.7679
Swallowing  9.23 (18.40) 10.80 (17.57) 40.00 (36.99) 18.75 (18.84) 0.8893
Senses problems  7.21 (19.46) 10.49 (18.58) 3.33 (7.46) 16.67 (24.62) 0.2302
Speech problems  9.31 (18.80) 8.64 (17.52) 28.89 (20.19) 22.22 (23.21) 0.7743
Trouble with social eating  10.81 (21.05) 7.41 (17.04) 25.00 (21.24) 22.22 (27.83) 0.5291
Trouble with social contact  6.85 (15.19) 6.67 (16.01) 16.00 (15.35) 23.33 (21.37) 0.9532
Less sexuality  10.81 (24.91) 7.41 (16.23) 10.00 (14.91) 27.78 (26.91) 0.6494
Teeth  19.82 (31.88) 6.17 (16.11) 26.67 (36.52) 41.67 (32.18) 0.3086
Opening mouth  8.11 (19.89) 8.64 (21.86) 20.00 (29.82) 33.33 (34.82) 0.9024
Dry mouth  18.92 (33.83) 35.80 (30.56) 40.00 (36.52) 41.67 (28.87) 0.0323
Sticky saliva  15.32 (26.75) 23.46 (30.40) 40.00 (36.52) 41.67 (28.87) 0.4405
Coughing  9.01 (16.94) 9.88 (24.13) 13.33 (18.26) 25.00 (28.87) 0.6952
Felt ill  8.11 (21.38) 6.17 (13.19) 20.00 (44.72) 36.11 (30.01) 0.3044
Pain killers  0.90 (5.48) 4.94 (20.05) 0.00 (0.00) 47.22 (33.21) 0.0065
Nutritional supplements  19.82 (31.88) 14.81 (23.27) 0.00 (0.00) 38.89 (34.33) 0.5308
Feeding tube  0.00 (0.00) 4.94 (20.05) 20.00 (44.72) 2.78 (9.62) 0.4293
Weight loss  1.80 (7.64) 1.23 (6.41) 13.33 (29.82) 8.33 (15.07) 0.9319
Weight gain  13.51 (25.41) 7.41 (16.88) 13.33 (18.26) 0.00 (0.00) 0.0490
Values are presented as mean (standard deviation). 
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groups (Table 3). 
The present study shows that three-years DFSRs in the surgery-
based and RT-based treatment groups were 74.7% and 75.7%,
respectively. Furthermore, our review of the literature showed
that CCRT appears to be slightly inferior to surgery with adju-
vant radiotherapy in terms of treatment outcomes. Our results
and review of literature lead us to believe that present CCRT is
likely to have an equal or only slightly worse result than surgery
plus RT. Of course, a large-scale prospective randomized trial is
required to prove the comparative oncologic results of these two
treatment approaches.
Quality of life 
QOL is a complex concept that reflects several aspects of life,
and an individual’s perception of overall well-being with regard
to disease and treatment-related symptoms is specifically called
“health-related QOL” (10). However, many reports use the two
terms interchangeably.
Several QOL assessment tools have been devised. According
to a structured review of QOL in head and neck cancer (11), the
most frequently used questionnaires are the EORTC (12), the
University of Washington Quality Of Life (UW-QOL), and the
Functional Assessment of Cancer Therapy (FACT) question-
naires. Of these, the EORTC questionnaire is most commonly
used, and has been validated in Korean-speaking sample (1).
Therefore, it was selected for our study. The EORTC question-
naire is an integrated system for assessing QOL in a wide range
of cancer patients. It is composed of core questions (QLQ-C30)
and supplementary tumor-specific questionnaire modules: for
lung cancer (QLQ-LC13), breast cancer (QLQ-BR23), head and
neck cancer (QLQ-HN35), esophageal cancer (QLQ-OES18),
ovarian cancer (QLQ-OV28), and so on. In the present study,
we used the EORTC QLQ-C30 and EORTC QLQ-HN35. 
From the 1990’s, QOL has been increasingly recognized as
an important outcome parameter in head and neck cancer, and
literally hundreds of papers have been published on that issue.
However, in the case of oropharyngeal cancer, generally accept-
ed conclusions are rare, because only dozens of studies have
been conducted, and these studies addressed their specific top-
ics, applied different enrollment criteria and used different
methods of analysis. 
Many physicians believe that oropharyngeal cancer surgery
is too invasive to be compatible with a good or even a tolerable
QOL. However, we resist this presumption. Current advances
in reconstruction allowed the oropharyngeal cancer surgery to
become less destructive. Recent studies on free-flap reconstruc-
tion have shown the acceptable QOL and functional status in
most cases, even after extensive ablative surgery (13-15). Although
these were longitudinal, cohort studies without control groups,
they at least showed that current surgical therapies offered good
treatment options with acceptable QOL. Our study result also
supports this conclusion. 
At our institution, surgical extent tends to be conservative,
nearly all T1 and most T2 primary tumors are resected intraoral-
ly, and even for advanced cases, mandibulotomy and segmental
mandibulectomy are avoided if possible. Three-dimensional
reconstructions are carried out in the majority of advanced cases.
We believe that this conservative surgical approach is likely to
achieve better QOL results without disturbing oncologic outcome. 
As for the results of the EORTC QLQ-C30 questionnaire,
cognitive functioning and social functioning were found to be
better in the surgery-based group. Although its relevance is
questionable and its mechanism is unclear, accumulating evi-
dence indicates an association between chemotherapy and cog-
nitive deterioration (16-19). The better social functioning score
of the surgery-based group is believed to reflect the shorter
duration of therapy and fewer sequelae as compared with the
RT-based group. Our conspicuous finding was that patients in
the surgery group suffered less from financial difficulties than
those in the RT-based group. We believe that this result is due
to the national medical insurance system in Korea, which charges
extremely low fees for surgery. Nausea and vomiting is a com-
mon complication of chemotherapy, thus poorer results of this
item in the RT-based group can be easily appreciated. Although
the majority of patients (78.8%) in the surgery-based group
received radiation or chemoradiation postoperatively, radiation
doses in the surgery group were significantly lower than those
in the RT-based group (5,878 cGy vs. 6,637 cGy). We think
that this difference in radiation dose might contribute to make a
difference in several QOL items, since the analysis after “compen-
sation” of radiation doses revealed that no items of the QLQ-
C30 were different. This analysis result is somewhat confusing.
It does not mean that the QOL results are truly identical but
implies that if the radiation doses had been the same, QOL results
would not have differed between the two groups. But in an
actual clinical setting, the radiation dose of the two treatment
groups will be different.
According to our EORTC QLQ-HN35 survey data, most
items revealed no significant differences between the two groups,
although members of the RT group had more problems with a
dry mouth, difficulties in weight gain, and were more depen-
dent on pain killers. A dry mouth appears to be an invariant
RT-associated problem. However, difficulty in weight gain and
greater pain found in the RT-based group have not been found
previously, and we ascribe this apparent discrepancy to our less
destructive surgery. Analysis after correction of radiation dose
was conducted again, and this time, differences in pain killers
(P=0.0021), weight gain (P=0.0198) items were still significant.
The interpretation of QOL data is not straightforward, and
some potential problems should be borne in mind. First, many
factors such as age, sex, marital status, comorbidity, malnutri-
tion, tumor location, stage, treatment modality, and time of
evaluation, etc. are known to affect QOL in patients with head
and neck cancer. In addition, many of these factors have beeninconsistently associated with QOL. For example, van der
Schroeff et al. (20) found that age had no independent impact
on QOL when they compared QOL in 24 older (≥70 years)
and 33 younger (45-60 years) patients, whereas Hammerlid et
al. (21) found that older patients scored significantly better for
emotional and social functioning than patients of <65, but sig-
nificantly worse for physical functioning and for various symp-
toms measures. Hence, potential confounders have to be well
controlled. In our study, T classification in the surgery-based
group turned out to be significantly lower than in the RT-based
group. We supposed that it might affect QOL results, thus, this
was compensated by subgroup analysis based on T classifica-
tion and using Spearman’s partial correlation analysis.
The second problem is that QOL scores change with time.
Many studies have found that QOL deteriorates during treat-
ment, recovers to some extent during the first year post-treat-
ment, and then stabilizes (14, 22-24). Besides, QOL may be
compromised before treatment (14). In this study, QOL was
evaluated just once in a cross-sectional fashion, and thus, we
cannot rule out the possibility that QOLs differed between the
two groups before the treatment, and this is our major draw-
back. Accordingly, a longitudinal study is required to further
investigate QOL issues.
Regarding previous comparisons of surgery-based and RT-
based treatments of oropharyngeal cancer from the QOL point
of view, many findings are inconsistent. Mowry et al. (25) failed
to find any difference between 17 and 18 patients of stages II-
IV who underwent surgery plus RT or CCRT, respectively.
Pourel et al. (26) administered EORTC QLQ-C30 and HN35
questionnaires to 113 patients, and found that QOLs were simi-
lar regardless of initial treatment modality (brachytherapy,
external beam RT, or surgery plus RT). Boscolo-Rizzo et al.
(10) compared QOL in 57 patients who had T3-4 oropharyn-
geal cancer after surgery plus postoperative RT (26 patients)
versus CCRT (31 patients) using EORTC QLQ-C30 & QLQ-
HN35. Physical and social functioning were found to be signifi-
cantly better in CCRT group. CCRT group was advantageous
in symptom items such as fatigue, pain, and swallowing, trouble
with social eating, trouble with social contact. However CCRT
was unfavorable in teeth, open mouth, dry mouth, and sticky
saliva items. Tschudi et al. (27) investigated QOL after three
different treatment modalities, namely, surgery alone, RT alone,
and surgery plus RT in 31, 19, and 49 patients, respectively.
EORTC QLQ-C30 revealed no significant differences between
the three treatment groups, although non-irradiated patients
had significantly fewer problems associated with swallowing,
social eating, social contact, dry mouth, sticky saliva, and mouth
opening, regardless of the primary treatment modality. Allal et
al. (28) assessed QOL after radical surgery with postoperative
RT and an RT boost with or without chemotherapy in 60 patients.
They used the Performance Status Scale for Head and Neck
Cancer (PSSHN) questionnaire which comprises eating in pub-
lic, understandability of speech, normalcy of diet, and the
EORTC QLQ-C30 questionnaire. No significant differences
were observed for T1-2 tumors, but patients with T3-4 tumors
showed highly significant differences that favored the RT group
for all three subscales. EORTC QLQ-C30 findings revealed that
T1-2 patients in the surgery group had better social function than
those in the RT group. In patients with T3-4 tumors, patients in
the surgery group suffered from more severe pain than those in
the RT group. 
In summary, treatment outcomes were found to be equal in
the surgery-based and RT-based groups, and patients in the
surgery-based group achieved better QOL scores for a few vari-
ables. Consequently, we cautiously infer that surgery-based
treatment is worth reconsidering as a first-line therapy as well
as CCRT for the treatment of oropharyngeal cancer.
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